Earnings call transcript: GE HealthCare Q1 2026 sees stock drop amid margin pressures

GE HealthCare reported Q1 2026 revenue of $5.1B, up 2.9% organically, but adjusted EBIT margin fell 150bps to 13.5% and adjusted EPS came in at $0.99, pressured by tariffs, supplier issues, and inflation. Management cut full-year adjusted EPS guidance by $0.15 to reflect about $250M of inflation headwinds, even as backlog hit a record $21.8B and the innovation pipeline advanced. Shares sold off 8.93% premarket and were trading near a 52-week low as investors focused on margin deterioration and weaker profitability.

Analysis

GEHC’s setup is a classic two-speed story: near-term margin compression from inputs/tariffs versus a much better 12-24 month revenue/margin mix as newer products clear and convert. The market is mostly punishing the cadence problem, but the second-order effect is that pricing power should improve precisely when the backlog begins to roll into higher-margin launches, which can create an earnings inflection in 2H26/2027 if execution holds.

The bigger winner may be the installed-base franchise, not the headline innovation pipeline. When management leans harder into pricing, service attach, and cloud/software monetization, the company can offset more of the cost shock without needing unit growth to accelerate dramatically; that shifts the burden away from capex cycles and toward recurring revenue. Competitively, that favors scaled OEMs with broad SKU portfolios and field coverage, while smaller point-solution vendors could face pressure if customers demand bundled workflows and more integrated procurement.

The key risk is that the inflation narrative becomes a proxy for broader operational slippage: supplier quality, China normalization, and PCS conversion all need to improve at once for the stock to stabilize. If input costs stay elevated into Q3 while reimbursement and pricing actions lag, estimates likely drift lower again, and the current selloff may only partially discount that. Conversely, any evidence that the cost spike is peaking and that new-product orders are converting faster would be enough to re-rate the shares quickly because expectations are now de-risked.

Key Decisions for Investors

• Buy GEHC on weakness only after evidence of sequential margin stabilization; target a 3-6 month bounce if Q2 confirms the inflation peak, with a stop if 2H guidance is revised lower again.
• Sell near-dated GEHC puts / structure a bullish put spread into the next print to monetize elevated implied volatility; the risk/reward improves if investors are overpricing a second guidance cut.
• Pair trade: long GEHC vs short a smaller medtech imaging/systems peer with less pricing power and weaker service mix over the next 1-2 quarters; GEHC should outperform if backlog conversion stays intact.
• For event-driven accounts, buy GEHC call spreads expiring in 6-9 months sized small; the upside catalyst is 2027 NPI visibility, while downside is capped by already-reset expectations and record backlog.
• Avoid chasing the stock until there is proof that PCS and China are no longer dilutive; this is a show-me name, not a catch-the-falling-knife trade.